AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31804680
Drug: Talc Poudrage
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talc Poudrage (4 g during thoracoscopy under moderate sedation)
Trial: 31804680
Drug: Talc Slurry
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talc Slurry (4 g via bedside chest tube with local anesthesia)
Trial: 29307999
Drug: dexlansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexlansoprazole 60 mg
Trial: 29307999
Drug: esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole 40 mg
Trial: 14993087
Drug: Drug and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug and alcohol abuse prevention education
Trial: 10977012
Drug: L+G (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L+G (insulin lispro + glyburide)
Trial: 10977012
Drug: NPH+G (bedtime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH+G (bedtime NPH insulin + glyburide)
Trial: 9384424
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 40 mg methylprednisolone with 1% lidocaine
Trial: 9384424
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution with 1% lidocaine (control group)
Trial: 1586601
Drug: Etretinate 25
RxNorm normalized name: etretinate 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate 25 mg orally daily for 6 months
Trial: 3543432
Drug: S6472 (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S6472 (375 mg, 2 times daily for 7 days)
Trial: 3543432
Drug: CCL (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCL (250 mg, 3 times daily for 7 days)
Trial: 3396471
Drug: Cefotaxime 2g
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2g 8‐hourly
Trial: 3396471
Drug: Cefoxitin 2g
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2g 6‐hourly
Trial: 3396471
Drug: Clindamycin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (900 mg 8‐hourly) and gentamicin 3 to 5 mg/kg/day in divided doses 8‐hourly
Trial: 31985099
Drug: Conventional pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacotherapy (CNT group)
Trial: 19438397
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg per day)
Trial: 19438397
Drug: Nevirapine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (400 mg per day)
Trial: 17447829
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 3-12 mg/day for 6 weeks
Trial: 9669447
Drug: Urapidil (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (30 mg)
Trial: 30632220
Drug: Valerian root
RxNorm normalized name: Valerian Root
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian root extract (VRE) 100 mg thrice daily
Trial: 16447240
Drug: High-dose doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose doxycycline (100 mg twice daily) plus methotrexate (MTX)
Trial: 16447240
Drug: Low-dose doxycycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxycycline (20 mg twice daily) plus methotrexate (MTX)
Trial: 11461801
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of investigational drug
Trial: 11461801
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of investigational drug
Trial: 11461801
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (e.g., carbamazepine or valproate)
Trial: 11461801
Drug: Investigational drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug (high dose)
Trial: 11461801
Drug: Investigational drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug (low dose)
Trial: 9490558
Drug: oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral iron therapy alone
Trial: 7930915
Drug: Pilocarpine mouthwash
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine mouthwash (5 mg three times a day)
Trial: 3555627
Drug: Methylene blue,
RxNorm normalized name: Methylene Blue, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue, 15 mg/day
Trial: 28760787
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support interventions including patient decision aids for primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy, and a clinical treatment outcomes algorithm for clinicians.
Trial: 23663881
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B immunoglobulin (HBIG; three 200 IU intramuscular injections given at four-week intervals starting from gestation week 28)
Trial: 23663881
Drug: No HBIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No HBIG injection
Trial: 23663881
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum HBV DNA ≥ 10⁷ copies/mL
Trial: 23663881
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum HBV DNA 10³-10⁶ IU/ml
Trial: 23663881
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum HBV DNA < 10³ IU/ml
Trial: 18679165
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (3.4 +/- 1.1 mL/d)
Trial: 2896423
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil
Trial: 29723105
Drug: Probiotic administration
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic administration for 4 weeks
Trial: 29723105
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration for 4 weeks
Trial: 25520127
Drug: 7‐day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐day standard triple therapy plus bismuth and probiotic
Trial: 25520127
Drug: 7‐day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐day standard triple therapy with placebo
Trial: 25520127
Drug: 14‐day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14‐day standard triple therapy plus bismuth and probiotic
Trial: 18698245
Drug: PEG interferon
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG interferon alpha 2b (1.0 microg/kg per week), ribavirin (800 mg/d) plus amantadine (200 mg/d)
Trial: 18698245
Drug: PEG interferon
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG interferon alpha 2b (1.0 microg/kg per week) plus ribavirin (800 mg/d)
Trial: 15854180
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon alpha-2b combined with lamivudine 100 mg/day
Trial: 8740313
Drug: rHuEPO 900
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO 900 U kg‐1 week‐1 with 6 mg kg‐1 day‐1 of iron for 4 weeks
Trial: 29342163
Drug: Doxylamine-pyridoxine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxylamine-pyridoxine (10 mg doxylamine and 10 mg pyridoxine, taken 2-4 times per day for 14 days)
Trial: 29342163
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablet taken with the same instructions)
Trial: 26947173
Drug: Warfarin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (25 mg)
Trial: 15657158
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment (6 to 9 million U, 3 times weekly for 26 to 88 weeks)
Trial: 2623215
Drug: Nicardipine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine administered intravenously or topically using iontophoresis or occlusive dressing
Trial: 28452885
Drug: Metabolic-targeted hypothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic-targeted hypothermia treatment (MTHT) group, targeting 50% to 60% rest metabolic ratio
Trial: 28452885
Drug: Body temperature-targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body temperature-targeted hypothermia treatment (BTHT) group, targeting body temperature of 32°C to 35°C
Trial: 18438829
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with methotrexate, sulfasalazine, and prednisone (group 3)
Trial: 18438829
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with methotrexate and infliximab (group 4)
Trial: 16284067
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg rectally, given as three doses every 12 hours starting the night prior to embryo transfer
Trial: 12676418
Drug: Multidimensional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional treatment protocol delivered by nurse practitioners (NP)
Trial: 3948474
Drug: Dihydroergotamine (DHE),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE), 0.5 mg im, twice a day from the day of surgery until full mobilization achieved
Trial: 26391030
Drug: Multi-modal tobacco
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal tobacco treatment education (MME)
Trial: 26391030
Drug: Traditional tobacco
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional tobacco treatment education (TE)
Trial: 10613168
Drug: Dorsiflexion night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsiflexion night splint for 3 months along with oral antiinflammatory medication, Achilles stretching exercises, and shoe recommendations
Trial: 10613168
Drug: Oral antiinflammatory
RxNorm normalized name: Arthriten Inflammatory Pain Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiinflammatory medication, Achilles stretching exercises, and shoe recommendations for 1 month
Trial: 10613168
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (with and without night splint)
Trial: 1773711
Drug: Purified pork
RxNorm normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purified pork insulin (PPI)
Trial: 7002185
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g four times daily for 2 days, then 0.5 g four times daily for the next 2 days
Trial: 22139541
Drug: Tongxinluo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo Capsule
Trial: 22139541
Drug: Kangxin Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangxin Capsule
Trial: 19098197
Drug: 3D sonography
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D sonography with perflubutane contrast agent
Trial: 17684211
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 10 mg tablet twice a day during hospitalization
Trial: 9205830
Drug: Eprosartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 200 mg orally every 12 h for 4 days
Trial: 9205830
Drug: Digoxin 0.6
RxNorm normalized name: medigoxin 0.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.6 mg orally alone
Trial: 8166054
Drug: Various therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various therapies designed to impact on progression of heart failure
Trial: 3308164
Drug: oral cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral cyclical combination of 2 mg estradiol valerate and cyproterone acetate
Trial: 3308164
Drug: percutaneous 17
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: percutaneous 17 beta‐estradiol, supplemented by 200 mg oral progesterone during the second year
Trial: 22789911
Drug: Telecare device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telecare device kit including monitoring of oxygen saturation, pulse rate, and respiration rate, with medication and purse-lip breathing reminders.
Trial: 23438937
Drug: Sertraline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (150 mg daily)
Trial: 16160624
Drug: Fluvoxamine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (200 mg daily)
Trial: 12749829
Drug: Lipopeptide antibiotics
RxNorm normalized name: oligopeptide 104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipopeptide antibiotics
Trial: 12749829
Drug: Peptide deformylase
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide deformylase inhibitors
Trial: 1928809
Drug: L-dopa 250
RxNorm normalized name: L-DOPA 250 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa 250 mg administered orally
Trial: 1928809
Drug: Domperidone 20
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 20 mg orally (peripheral DA2 dopamine receptor blocker)
Trial: 6137167
Drug: Lormetazepam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (oral and intravenous)
Trial: 30700332
Drug: One-lead handheld
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-lead handheld ECG recordings twice daily and extra recordings in case of palpitations.
Trial: 29668467
Drug: Bilateral ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound guided rectus sheath block with 40 ml of 0.25% bupivacaine after induction of general anesthesia (Group II)
Trial: 15105384
Drug: Hysteroscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic surgery plus intrauterine application of ACP gel (10 ml)
Trial: 9839106
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg/day)
Trial: 11437862
Drug: Glibenclamide (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5.0 mg/day)
Trial: 1853146
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole once daily
Trial: 8020815
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g sucralfate twice daily
Trial: 2920066
Drug: GE +
RxNorm normalized name: New Image Flange + 1" Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GE + GU (gemfibrozil + guar gum) 15 g/day
Trial: 29206666
Drug: Diclofenac phonophoresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac phonophoresis with combined therapy
Trial: 29206666
Drug: Ultrasound (US)
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US) with coupling gel
Trial: 16481224
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg alone
Trial: 16481224
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg with 2‐h spaced calcium carbonate 500 mg thrice daily
Trial: 12795568
Drug: Behavioral family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral family counseling (BFC) plus individual treatment (naltrexone daily in presence of family member)
Trial: 12795568
Drug: Individual-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-based treatment (IBT; naltrexone with no family involvement)
Trial: 26856926
Drug: DP-R202 300
RxNorm normalized name: DP-303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP-R202 300 mg once daily
Trial: 26856926
Drug: Anplag Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anplag Tab 100 mg TID
Trial: 25282317
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin therapy (rosuvastatin 40 mg or atorvastatin 80 mg)
Trial: 22704854
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine (average end titration dose of 78 mg morphine/d)
Trial: 22704854
Drug: Weight-matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-matched placebo capsules
Trial: 19449118
Drug: Neoadjuvant LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant LHRH agonist plus estramustine phosphate (EMP) for 6 months until completion of the 3D-CRT (EMP group, n = 20)
Trial: 19449118
Drug: Neoadjuvant LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant LHRH agonist alone (LHRH group, n = 19)
Trial: 17035932
Drug: Spironolactone 300
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 300 mg
Trial: 15721570
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Attachment Based Family Therapy (ABFT)
Trial: 8607621
Drug: Oral 5'-DFUR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5'-DFUR
Trial: 8607621
Drug: Oral 5'-DFUR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5'-DFUR plus intratumor and intracutaneous OK-432
Trial: 108804
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate inhalation solution
Trial: 26744141
Drug: Fluoridated implants
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated implants in the maxilla
Trial: 22897123
Drug: Mentalization-based psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based psychotherapy (MBT) for 2 years, twice weekly, combined individual and group therapy
Trial: 22897123
Drug: Supportive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive group therapy for 2 years, biweekly
Trial: 21295639
Drug: Anesthesiologist-managed propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesiologist-managed propofol sedation (propofol infusion group)
Trial: 11703246
Drug: Epidural patient-controlled
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural patient-controlled analgesia (PCA) using pethidine (bolus 10 mg, lockout interval 10 min, 4-h maximum dose 3 mg.kg(‐1))
Trial: 11703246
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) using pethidine (bolus 10 mg, lockout interval 10 min, 4-h maximum dose 3 mg.kg(‐1))
Trial: 10322828
Drug: Zhiganle capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhiganle capsule (ZGLC)
Trial: 10322828
Drug: Dongbao Gantai
RxNorm normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dongbao Gantai (DBGT) tablets
Trial: 8300840
Drug: Misoprostol 400
RxNorm normalized name: Misoprostol 400 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 400 micrograms orally (up to three doses)
Trial: 8300840
Drug: Gemeprost vaginal
RxNorm normalized name: gemeprost
DrugBank: Gemeprost (DB08964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemeprost vaginal pessary 1 mg (up to five doses)
Trial: 29866947
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) of chemotherapy
Trial: 21029638
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release tablets
Trial: 18230966
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg x day(-1)
Trial: 12915747
Drug: Almitrine 100
RxNorm normalized name: almitrine
DrugBank: Almitrine (DB01430)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine 100 mg per day